Thermal liquid biopsy (Tlb): A predictive score derived from serum thermograms as a clinical tool for screening lung cancer patients
| Autor: | Sonia Vega, Angel Lanas, Adrián Velázquez-Campoy, Alberto Rodrigo, Dolores Isla, Olga Abian, Jorge L. Ojeda, Oscar Sanchez-Gracia |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III, European Commission, Ministerio de Economía y Competitividad (España), Diputación General de Aragón, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Generalized linear models Population cancer screening program lcsh:RC254-282 Article 03 medical and health sciences 0302 clinical medicine Differential scanning calorimetry Internal medicine Biopsy medicine Liquid biopsy Lung cancer education Survival rate serum sample education.field_of_study medicine.diagnostic_test liquid biopsy business.industry Mortality rate Cancer generalized linear models medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lung cancer 030104 developmental biology Serum sample Cancer screening program 030220 oncology & carcinogenesis Diagnostic odds ratio differential scanning calorimetry business |
| Zdroj: | Cancers Cancers, Vol 11, Iss 7, p 1012 (2019) Digital.CSIC. Repositorio Institucional del CSIC instname Digital.CSIC: Repositorio Institucional del CSIC Consejo Superior de Investigaciones Científicas (CSIC) Volume 11 Issue 7 Zaguán. Repositorio Digital de la Universidad de Zaragoza |
| Popis: | 20 pags, 5 figs, 7 tabs Risk population screening programs are instrumental for advancing cancer management and reducing economic costs of therapeutic interventions and the burden of the disease, as well as increasing the survival rate and improving the quality of life for cancer patients. Lung cancer, with high incidence and mortality rates, is not excluded from this situation. The success of screening programs relies on many factors, with some of them being the appropriate definition of the risk population and the implementation of detection techniques with an optimal discrimination power and strong patient adherence. Liquid biopsy based on serum or plasma detection of circulating tumor cells or DNA/RNA is increasingly employed nowadays, but certain limitations constrain its wide application. In this work, we present a new implementation of thermal liquid biopsy (TLB) for lung cancer patients. TLB provides a prediction score based on the ability to detect plasma/serum proteome alterations through calorimetric thermograms that strongly correlates with the presence of lung cancer disease (91% accuracy rate, 90% sensitivity, 92% specificity, diagnostic odds ratio 104). TLB is a quick, minimally-invasive, low-risk technique that can be applied in clinical practice for evidencing lung cancer, and it can be used in screening and monitoring actions. This research was funded by Miguel Servet Program from Instituto de Salud Carlos III (CPII13/00017 to OA); Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III, and European Union (ERDF/ESF, 'Investing in your future') (PI15/00663 and PI18/00349 to OA, and PI17/01109 to AL); Spanish Ministry of Economy and Competitiveness (BFU2016-78232-P to AVC); Diputación General de Aragón (Protein Targets and Bioactive Compounds Group – E45_17R to AVC, and Digestive Pathology Group – E25_17R to OA and AL); and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|